中國金融發展(03623.HK):未償還本金額6400萬港元可換股債券本息將支付予買方
格隆匯 1 月 29日丨中國金融發展(03623.HK)公佈,公司與買方訂立認購協議及進一步修訂,據此公司有條件同意發行而買方有條件同意認購本金總額為8400萬港元的可換股債券,惟須遵守及受限於認購協議及進一步修訂所載的條款及條件。可換股債券於2020年1月31日到期,根據可換股債券的條款及條件,買方確認、同意及知悉,剩餘的可換股債券已延期至2021年1月31日。
於公吿日期,原本金額約23.81%(相當於2000萬港元)的可換股債券已轉換為換股股份。未償還本金額6400萬港元連同全部應計及未付利息將由公司按照訂約方共同商定的新條款支付予買方。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.